Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Gusto Global
AddedFeb 15, 2024
UpdatedJun 18, 2026
Gusto Global

Gusto Global

Seed

Gusto Global develops live biotherapeutic products targeting inflammatory bowel disease and cancer.

HQ
Morrisville, NC, US
Founded
2015
Overview
Compare
Fundraising
Employees
News
Website

Gusto Global is a biotechnology company developing live biotherapeutic products and microbiome-based diagnostics. Its therapeutic pipeline includes GUT-108, a defined bacterial consortium for inflammatory bowel disease, and GUT-115, a candidate designed to enhance immune-checkpoint response in oncology patients. The company also runs Tapestry, a fragment-sequencing test that analyzes microbial cell-free DNA in blood for non-invasive disease detection.

Founded in 2015 in North Carolina, Gusto Global emerged from technology licensed by University of Chicago researchers Jack Gilbert and John Alverdy. The company operates the GUST+ bioinformatics platform combining microbial ecology, metagenomics, and machine learning, and conducts research collaborations with the Crohn's and Colitis Foundation, the University of North Carolina, and the National Institutes of Health.

Gusto Global - Similar Companies

Gemelli Biotech logo

Gemelli Biotech

gemellibiotech.com

Petri Bio logo

Petri Bio

petribio.com

Persephone Biosciences logo

Persephone Biosciences

BioPlx logo

BioPlx

Injoy logo

Injoy

injoy.bio

The BioCollective logo

The BioCollective

Envivo Bio logo

Envivo Bio

envivo.bio

GenieBiome logo

GenieBiome

Siolta Therapeutics logo

Siolta Therapeutics

Solarea Bio logo

Solarea Bio

solareabio.com

Fortis Biosciences logo

Fortis Biosciences

Notitia Biotechnologies logo

Notitia Biotechnologies

notitiabio.com

FloraSeq logo

FloraSeq

Biomiic logo

Biomiic

BrilliantBiome logo

BrilliantBiome

brilliantbiome.com

Gusto Global - Quick Facts

Who are Gusto Global's competitors?

Companies similar to Gusto Global include Gemelli Biotech, Petri Bio, Persephone Biosciences and BioPlx.

When was Gusto Global founded?

Gusto Global was founded in 2015.

Where is Gusto Global's headquarters located?

Gusto Global's headquarters is located in Morrisville, NC, US.

When was Gusto Global's last funding round?

Gusto Global's most recent funding round was for $1.9M (USD) in September 2022.

How much has Gusto Global raised to-date?

As of Sep 21, 2022, Gusto Global has raised a total of $5.5M (USD).

Gusto Global - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • AI
  • Microbiology
Geographic Exposure
  • Global
Model
  • Platform
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Biotherapeutics
Tags
  • Healthcare
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 4 more industry codes
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified